Research Laboratories RNA Treatment 
Drug Target Review
JULY 15, 2025
Their latest assay processes four to 24 libraries per batch and detects gene amplifications, fusions, deletions and other cancer biomarkers from both DNA and RNA inputs. Their latest assay processes four to 24 libraries per batch and detects gene amplifications, fusions, deletions and other cancer biomarkers from both DNA and RNA inputs.
The Pharma Data
MARCH 8, 2021
At a time where there is unmet need for antiviral treatments against SARS-CoV-2, we are encouraged by these preliminary data.”. Molnupiravir has been shown to be active in several models of SARS-CoV-2, including for prophylaxis, treatment, and prevention of transmission, as well as SARS-CoV-1 and MERS. About Molnupiravir.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
The Pharma Data
JULY 12, 2021
It continues to be critically important to advance potential antiviral treatments to address the devastating impact of COVID-19 globally,” said Dr. Roy Baynes, senior vice president and head of global clinical development, chief medical officer, Merck Research Laboratories. “If View the full release here: [link]. “It
The Pharma Data
JULY 12, 2021
Joan Butterton, vice president, Global Clinical Development, Infectious Diseases, Merck Research Laboratories. “We We believe that islatravir has the potential to serve as the foundation of future treatment and prevention regimens, and we look forward to sharing new data from our HIV portfolio and pipeline.”. Abstract 2361.
The Pharma Data
NOVEMBER 18, 2021
A review by the external Data Monitoring Committee (eDMC) determined that this effect was related to treatment with the combination of ISL08507; the greatest decreases were seen in the arms of the study receiving the highest doses of MK-8507 (200 mg and 400 mg). The company has notified investigators and paused development of MK-8507.
The Pharma Data
OCTOBER 25, 2021
At 48 weeks, both trials met their primary efficacity endpoint of chance of actors with HIV-1 RNA situations ? Doravirine is approved for the treatment of grown-ups with HIV-1 in combination with other antiretrovirals, as a single agent (PIFELTRO) and a element of a single- tablet authority (DELSTRIGO; DOR/ 3TC/ TDF).
Drug Target Review
AUGUST 28, 2024
What are the main challenges currently faced in the treatment of chronic liver diseases, and how does Resolution Therapeutics aim to address these challenges? Dr Brass has published over 85 peer reviewed articles and more than 200 abstracts, primarily in the field of hepatology, in both the areas of clinical and basic science research.
Expert insights. Personalized for you.
92 
Let's personalize your content